Sponsored by the Academy for Continued Healthcare Learning.
Supported by an educational grant from Portola Pharmaceuticals, Inc.
In this activity, a three-faculty panel of experts discuss clinical situations with emergent needs for direct oral anticoagulant (DOAC) reversal. Faculty are featured via a video-recorded conference, complete with an accompanying PowerPoint presentation. This virtual forum provides an objective, non-judgmental review of adverse DOAC outcomes and systematic process changes regarding situations where DOAC reversal is warranted.
Clinicians require comprehensive knowledge of available and emerging DOAC reversal agents to appropriately apply them in emergent clinical situations. The goal for this activity is to guide clinical decisions, ranging from application of reversal approaches to resumption of DOAC therapy and timing after a patient experiences bleeding or thromboembolism.
The activity is intended for hospitalists, cardiologists, primary care physicians, nurses, and other clinicians who manage anticoagulation.
Upon completion of this activity, participants will be able to:
Outline current approaches and challenges to management of bleeding in patients receiving DOACs
Compare and contrast available and emerging reversal agents for DOACs, including their mechanisms of action and available data
Discuss approaches to DOAC reversal across diverse patient populations
Conflict Of Interest Disclosure Policy
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
Christian T. Ruff, MD, MPH (Chair) Assistant Professor of Medicine, Harvard Medical School Associate Physician, Brigham and Women's Hospital Boston, MA
Elaine Hylek, MD, MPH Professor of Medicine, Boston University School of Medicine Medical Director - Thrombosis Clinic and Anticoagulation Service, Boston Medical Center Boston, MA
Dr. Hylek discloses the following: Consultant: Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co., Daiichi Sankyo, Janssen Pharmaceuticals, Medtronic, Pfizer Inc., Portola Pharmaceuticals, Inc. Scientific Symposia: Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co., DOASENSE GmbH, Pfizer Inc.
Bryan Kluck, DO Cardiologist Lehigh Valley Health Network Allentown, PA
Dr. Kluck discloses the following: Speakers Bureau: Janssen Pharmaceuticals, Boehringer Ingelheim GmbH
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of Off-Label, Investigational, or Experimental Drug Use: Agents under investigation for reversal
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This activity will take 30 minutes to complete. To obtain credit, a score of 66% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact: Alicia Graf firstname.lastname@example.org